Ƙwararren Ƙwayoyin Labaran Lyphoma (ALCL) wani nau'i ne wanda ba a sani ba na lymphoma ba na Hodgkin (NHL) wanda ya fito ne daga T-cell. T-kwayoyin halitta nau'in kwayoyin halitta ne wanda ke kare jiki daga cututtuka. Akwai nau'o'i biyu na lymphoma cellular anaplastic, nau'i na farko, da nau'in cututtuka na farko.
- Nau'in tsarin ya shafi tasirin lymph da sauran gabobin.
- Irin nau'in cututtuka yana shafar ƙwayar fata
Nau'in Farko na Farko
Irin tsarin ALCL na yaudara yana shafi duka yara da manya. A cikin tsofaffi, ƙananan lymphoma ne mai wuya, amma a cikin yara, ALCL lambobi na 1 cikin 10 na dukkanin lymphomas. Yawancin mutane da wannan lymphoma na farko suna kokawa game da ƙananan lymph nodes , ko da yake yana da wuya rinjayar hanji ko kasusuwa ba tare da haɗarin lymph nodes ba.
An gane ganewar asali tare da biopsy daga kogin lymph ko kwayoyin da aka shafi. Aikin kwayar halitta yana nuna alamar ta musamman na wannan lymphoma a ƙarƙashin microscope. Masanin ilimin likita zai gwada kwayar halittu tare da alamun lymphoma na musamman waɗanda zasu iya gano wani kwayoyin halitta wanda ake kira CD30 akan farjin kwayar cutar Kanada a ALCL. Gabatarwar wannan murfin CD30 ya bambanta da sauran nau'o'in NHL .
Wani gwaji na alama don furotin na musamman, wanda ake kira ALK protein, an yi shi. Ba dukkanin mutane da ALCL sun tabbata ga ALK ba.
Wadanda suke da ALK sunada mafi alhẽri bayan magani fiye da wadanda ba su da. Yara sun fi samun alamar ALK fiye da manya.
Da zarar an tabbatar da ganewar asali na ALCL, ana gudanar da jerin gwaje-gwajen don gano hanyar lymphoma .
An yi amfani da ALCL na asali tare da chemotherapy. Sakamakon gwaje-gwajen yana da kyau sosai, musamman ga waɗanda suke ALK-tabbatacce.
Rituximab , wanda ake amfani da shi a cikin ƙananan jini, wanda aka yi amfani da shi a mafi yawan siffofin NHL ba a amfani dasu a ALCL ba saboda baiyi aiki ba don lymphomas T-cell. Maimakon haka, Brentuximab vedotin (Adcetris) yana hari da kwayar CD30 kuma FDA ta amince da shi a 2011 don maganin ALCL a cikin wadanda ke fama da cutar da suka rage bayan magani ko wanda cutar ta dawo bayan nasarar da ta samu nasara.
Nau'in Harshen Farko
Irin nau'in ALCL mai cututtuka yana shafar ƙwayar fata. Wannan shi ne karo na biyu na lymphoma ba Hodgkin wanda ke shafar fata - bayan tantanin lymphoma T-cell cututtuka (CTCL) . ALCL na fata har yanzu yanayin da ya fi dacewa, wanda yafi rinjaye tsofaffi.
Abokan da suka shafi wadanda suka shafi wadanda suka kamu da cutar sun fara sanarwa ko kuma ulcers a kan fata. Zuwa ziyara a likita yakan haifar da sashin jikin mutum, wanda ya tabbatar da ganewar asali. Ana buƙatar nazarin Marker don kwayoyin musamman CD30 don lakafta cutar kamar yadda ALCL.
Kimanin 1 cikin 4 mutane tare da ALCL na fata sun shafi kwayoyin lymph kusa da fata na nodules ko ulcers. Za a iya gwada gwaje-gwaje don yin sarauta daga lymphoma a cikin kirji da ciki. Za a iya gwada gwaji mai laushi a matsayin ɓangare na bincike na yau da kullum.
ALCL na fata yana da matsala mai kyau. Wannan cuta ne mai raguwa wanda ke da wuya barazanar rai.
A wasu marasa lafiya, yana iya ɓacewa ba tare da wani magani ba. Ga wadanda ke da raunin fata sun iyakance zuwa wani karamin yanki, radiation far ne magani na zabi. Wadanda ke da kullun fata suna iya magance su da ƙananan maganin miyagun ƙwayoyi da ake kira methotrexate, a cikin nau'i na baki ko injections.
Sources:
FDA Approval for Brentuximab Vedotin, Cibiyar Cancer ta kasa, ranar 1 ga Yuli, 2013.
Tsarin yara na kananan yara Lymphoma Treatment-domin masu kiwon lafiya (PDQ®), Cibiyar Cancer ta Cibiyar Kanada, updated 1/26/2016.
Adult Non-Hodgkin Lymphoma Jiyya-domin masu kiwon lafiya (PDQ®). Cibiyar Cancer ta Kasa. sabunta ranar 1/15/2016.